Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284849 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Phase 3 study of CRC, Colorectal Cancer, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT07284849: Recruiting Phase 3 study of CRC, Colorectal Cancer, sponsored by Incyte Corporation.
NCT07284849 is a Phase 3 study of CRC, Colorectal Cancer that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 700 participants, above the 251-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284849, a Phase 3 study of CRC, Colorectal Cancer, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Primary Outcome
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Placebo
- DRUG FOLFOX
- DRUG INCA33890
Study Locations (20)
Florida
- Florida Oncology & Hematology - Fort Myers
- University of Florida Health - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
- Advent Health - Orlando
- Orlando Health Cancer Institute Downtown Orlando - Orlando
- Ascension Sacred Heart Pensacola - Pensacola
- Tampa General Hospital-Cancer Institute - Tampa
California
- Toi Clinical Research - Cerritos
- Los Angeles Cancer Network - Fountain Valley
- Providence Medical Foundation - Fullerton
- Long Beach Medical Center - Long Beach
- University of California Los Angeles Health - Los Angeles
Arizona
- The University of Arizona Cancer Center - Tucson
- Roche Tissue Diagnostics, Companion Diagnostics - Tucson
Georgia
- Piedmont Cancer Institute - Locust Grove
- Northwest Georgia Oncology Centers - Marietta
Colorado
- Sarah Cannon Research Institute Scri Oncology Partners - Aurora
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- George Washington University - Washington D.C.
Hawaii
- University of Hawaii Cancer Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2029-09-28 |
| Phase | Phase 3 |
What NCT07284849 shows while recruiting
NCT07284849 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 251-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (179% higher).
The record links to 1 condition, with CRC, Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07284849 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07284849 about?
NCT07284849 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer". The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
What is the current status of trial NCT07284849?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2026-03-05. Estimated completion is 2029-09-28.
What conditions does trial NCT07284849 study?
This clinical trial studies the following conditions: CRC, Colorectal Cancer.
What interventions are being tested in trial NCT07284849?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (DRUG), FOLFOX (DRUG), INCA33890 (DRUG).
Who is sponsoring clinical trial NCT07284849?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284849 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CRC, Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284849's enrollment target sits among peer trials
700 1st of 10 higher than 10 of 10 other CRC, Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other CRC, Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
RECRUITING · NA
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
RECRUITING
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI